Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Share-based Compensation: 2011-2024

Historic Share-based Compensation for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $74.6 million.

  • Ptc Therapeutics' Share-based Compensation fell 1.67% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.3 million, marking a year-over-year decrease of 0.83%. This contributed to the annual value of $74.6 million for FY2024, which is 26.59% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Share-based Compensation of $74.6 million as of FY2024, which was down 26.59% from $101.6 million recorded in FY2023.
  • Ptc Therapeutics' Share-based Compensation's 5-year high stood at $110.3 million during FY2022, with a 5-year trough of $70.3 million in FY2020.
  • Over the past 3 years, Ptc Therapeutics' median Share-based Compensation value was $101.6 million (recorded in 2023), while the average stood at $95.5 million.
  • In the last 5 years, Ptc Therapeutics' Share-based Compensation surged by 66.91% in 2020 and then decreased by 26.59% in 2024.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Share-based Compensation stood at $70.3 million in 2020, then soared by 47.19% to $103.5 million in 2021, then climbed by 6.59% to $110.3 million in 2022, then declined by 7.88% to $101.6 million in 2023, then decreased by 26.59% to $74.6 million in 2024.